Cannabis Takeover Battle
Curaleaf Bids Hostile Takeover for Aurora Cannabis, Offering $4.00 per Share Directly to Shareholders
Key Points
The offer is capped at US$5.00 per Aurora share, with the Curaleaf stock component potentially decreasing if Curaleaf's 20-day VWAP climbs above C$17.05, effectively limiting the total consideration for high Curaleaf share prices.
The bid requires more than 50% of independently held shares to be tendered and two-thirds on a fully diluted basis, regulatory clearances, and that Aurora’s shareholder rights plan not obstruct the transaction; the offer expires on December 1 at 5 p.m. Mountain Time.
Curaleaf privately approached Aurora about the deal in June and July prior to going public, and says the proposal was built from public filings because Aurora would not open its books.
Curaleaf cites macro-market factors such as softer medical reimbursement in Canada and Germany as part of its rationale, tying the bid to a broader plan for cross-border, multi-country expansion.
Curaleaf Holdings has launched a hostile takeover bid for Aurora Cannabis, going directly to shareholders after what it calls a failed attempt to negotiate a deal with Aurora's board. The offer values Aurora at US$4.00 per share — a 45% premium to Aurora's 30-day average price — and puts the total deal at roughly US$260 million, according to BNN Bloomberg.
Curaleaf CEO Boris Jordan framed the move as putting the decision in shareholders' hands. Aurora has pushed back, saying it never blocked talks and is focused on executing its own plan. The bid is open until December 1.
How the US$4.00 Offer Is Structured
Each Aurora share would receive 0.3463 Curaleaf subordinate voting shares plus US$0.75 in cash, according to MarketWatch. The stock portion comes with a cap: if Curaleaf's 20-day average share price rises above C$17.05, the number of shares given per Aurora share drops. Total consideration cannot exceed US$5.00 per share.
The deal has no financing conditions and no due-diligence requirements attached. Curaleaf built the offer using Aurora's public filings alone, since Aurora would not open its books. For the bid to succeed, more than 50% of independently held shares must be tendered, and two-thirds of all fully diluted shares must also agree.
Months of Private Talks Led to the Hostile Move
Curaleaf first approached Aurora privately in June and July, Yahoo Finance reported. When those talks went nowhere, Curaleaf took the offer public. The company says Aurora's board was unresponsive — Aurora disputes this, saying it never discouraged dialogue and has not seen a full, books-based proposal.
Aurora says it is focused on its own business strategy and sees no need to engage with an offer built on public data. The gap between both sides on process — not just price — appears to be a key sticking point heading into the December 1 deadline.
A Combined Company Spanning 17 Countries
Curaleaf projects the merged company would operate in 17 countries, with over US$1.5 billion in trailing revenue and US$350 million in adjusted EBITDA — a measure of operating profit before certain costs. Curaleaf calls the tie-up a platform for multi-country growth that neither company could build alone.
The rationale also includes macro headwinds. Curaleaf cited softer medical cannabis reimbursement in both Canada and Germany as pressure on Aurora's standalone outlook, according to Head Topics. A larger, diversified company, Curaleaf argues, would be better positioned to absorb those shifts.
Aurora's Shareholder Rights Plan Could Block the Deal
One key condition is that Aurora's shareholder rights plan — sometimes called a 'poison pill' — cannot be used to block the transaction. Rights plans are tools that make hostile takeovers more expensive by flooding the market with new shares. Curaleaf needs this hurdle cleared before the deal can close.
Regulatory approvals are also required. The bid expires at 5 p.m. Mountain Time on December 1. If Aurora's board continues to resist and shareholders don't tender enough shares, the offer lapses. Curaleaf has given itself very little room to renegotiate, having already committed to no due-diligence conditions.
Sentiment
Mostly PositivePublishers
10
Articles
26
Reach
36
